Although the introduction of TNF biological blockers into clinical practice has significantly improved the treatment of inflammatory conditions such as IBDs and juvenile idiopathic arthritis, patients treated with these agents may experience LoR and relapse of the disease [7]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.